FindTrial
Sign In

Analysis of factors related with efficacies and safeties of mogamulizumab treatments for adult T-cell leukemia/lymphoma patients.

Ad-hoc analysis of factors related with efficacies and safeties of mogamulizumab single agent or VCAP/AMP/VECP/mogamulizumab combination therapy for adult T-cell leukemia/lymphoma patients based on clinical trials and research results. - Ad-hoc analysis of factors related with efficacies and safeties of mogamulizumab single agent or VCAP/AMP/VECP/mogamulizumab combination therapy for adult T-cell leukemia/lymphoma patients.

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000049135
Enrollment
151
Registered
2022-10-17
Start date
2022-09-26
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult T-cell leukemia/lymphoma

Interventions

None listed

Sponsors

Kyowa Kirin Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients whose data was recorded participating the flowing clinical trials and clinical research: Phase 2 clinical trial investigating mogamulizumab efficacy and safety for relapsed ATL patients Phase 2 clinical trial comparing mogamulizumab efficacy and safety with investigator's choice for relapsed/refractory ATL patients Phase 2 clinical trial comparing efficacy and safety of mLSG15+mogamulizumab combination therapy with mLSG15 alone for untreated ATL patients and following clinical research.

Exclusion criteria

Exclusion criteria: No specific criteria

Design outcomes

Primary

MeasureTime frame
Progression free survival—

Secondary

MeasureTime frame
Overall survival Best response Safety—

Countries

Japan,North America,South America,Europe

Contacts

Public ContactYukihiro Nishio

Kyowa Kirin Co., Ltd. Medical Affairs

hqmarinkensuit.sh@kyowakirin.com03-5205-7200

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026